價(jià)格 | 詢價(jià) |
包裝 | 1盒 |
最小起訂量 | 1盒 |
發(fā)貨地 | 上海 |
更新日期 | 2025-05-06 |
中文名稱:Cathepsin G Inhibitor I | 英文名稱:Cathepsin G Inhibitor I |
CAS:429676-93-7 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 429676-93-7 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號(hào) | 型號(hào) |
Cathepsin G Inhibitor I | 500ug 1mg 5mg | 429676-93-7 | EY-Y0163999 |
Cas No.429676-93-7
別名 N/A
化學(xué)名 [2-[3-[(1-benzoylpiperidin-4-yl)-methylcarbamoyl]naphthalen-2-yl]-1-naphthalen-1-yl-2-oxoethyl]phosphonic acid
分子式 C36H33N2O6P
分子量 620.64
溶解度 ≥ 10.35mg/mL in DMSO
儲(chǔ)存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
IC50: 53 nM
Cathepsin G (EC 3.4.21.20, chymotrypsin-like proteinase, neutral proteinase) is an enzymatic protein belonging to the peptidase or protease families. In humans, it is coded by the CTSG gene. Cathepsin G Inhibitor I is a potent, selective, reversible, competitive, non-peptide inhibitor of cathepsin G.
In vitro: Cathepsin G Inhibitor I shows reversible, competitive inhibition with IC50 and Ki values of 53 ± 12 (N = 10) and 63 ± 14 nM (N = 5), respectively. Another attribute of Cathepsin G Inhibitor I relates to its selectivity vs other serine proteases. It weakly inhibits chymotrypsin (Ki = 1.5 ± 0.2 μM), and poorly inhibits (<50% inhibition at 100 μM) thrombin, factor Xa, factor IXa, plasmin, trypsin, tryptase, proteinase 3, and human leukocyte elastase [1].
In vivo: Cathepsin G Inhibitor I is currently in in-vitro investigation and no animal in vivo study is ongoing [1].
Clinical trial: Cathepsin G Inhibitor I is currently in the preclinical development and no clinical trial is ongoing.
Reference:
[1] Greco MN, Hawkins MJ, Powell ET, Almond HR Jr, Corcoran TW, de Garavilla L, Kauffman JA, Recacha R, Chattopadhyay D, Andrade-Gordon P, Maryanoff BE. Nonpeptide inhibitors of cathepsin G: optimization of a novel beta-ketophosphonic acid lead by structure-based drug design. J Am Chem Soc. 2002;124(15):3810-1.
成立日期 | 2014-06-05 (11年) | 注冊(cè)資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬(wàn)以內(nèi) |
主營(yíng)行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營(yíng)模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP3年
|
上海鴻肽生物科技有限公司
|
2025-04-10 | |
¥120 |
VIP6年
|
山東萍聚生物科技有限公司
|
2025-05-06 | |
¥110 |
VIP6年
|
南京松冠生物科技有限公司
|
2025-05-04 | |
¥1029.90 |
VIP13年
|
上海阿拉丁生化科技股份有限公司
|
2025-03-24 |